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ABSTRACT 
Background: Thalassemia patients need repeated transfusion that lead to increased blood ferritin level and 
iron overload in the heart and liver. Because the roles of hepcidin antimicrobial peptide (HAMP) and 
hemocromatosis protein (HFE) in iron metabolism have been confirmed, this study investigated the effects of 
these gene's polymorphisms on blood ferritin levels and iron overload in the heart and liver in patients with 
beta thalassemia major 
Materials and Methods: This cross-sectional study was conducted on 91 patients referring to the Hajar 
Hospital in Shahrekord, Iran in 2015. After the blood samples were collected, the ferritin levels were 
measured, DNA was extracted from the blood cells, and the types of polymorphisms were determined using 
PCR-RFLP. Data of MRI T2* in the heart and liver were drawn from the patients' medical files. Data analysis 
was conducted by t-test, chi-square test, Fisher's exact test, and Pearson correlation coefficient. 
Results: There was no significant correlation between blood ferritin level and c.-582 A>G polymorphisms of 
hepcidin gene (p=0.58), and H63D of HFE gene (p=0.818). In addition, there was no significant association 
between the polymorphisms and heart and liver MRI, but there was a significant association between blood 
ferritin level and qualitative heart and liver MRI (r=-0.34, p=0.035 and r=-0.001, p=0.609, respectively).  
Conclusion: In patients with β-thalassemia major, the presence of c.-582A>G HAMP and H63D HFE 
polymorphisms is not effective on blood ferritin level and iron overload in the heart and liver in the studied 
region. 
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INTRODUCTION 
   β-Thalassemia is the most common inherited 
anemic disorder in Iran; this disorder is caused by  
mutations in β globin gene. β-Thalassemia-
associated anemia occurs due to decreased β globin 
chain synthesis, increased degradation of available 
red blood cells (RBC) and short RBC survival1,2. This 
disorder is associated with various secondary 
complications such as extramedullary 
hematopoiesis, splenomegaly, iron overload, and 
blood-borne infections. The main cause of mortality 
in patients with transfusion-dependent thalassemia 
is iron overload-associated cardiomyopathy2. 
Ferritin is the main form of iron reserve in the body 
which is found mainly in reticuloendothelial system, 
hepatocytes, spleen, and bone marrow. Besides 
that, small amounts of ferritin can also be found in 
circulating plasma3. Ferritin concentration 
represents iron reserves in the body4. Iron 
metabolism in the body is regulated by several 
genes, including hepcidin antimicrobial peptide 
(HAMP) and human hemocromatosis (HFE, high Iron 
Fe) genes2,5.  
Hepcidin that is mainly synthesized by hepatocytes 
plays a role in the control of iron absorption and 
recycling. Hepcidin regulation in hepatocytes is 
affected by certain factors such as the amount of 
available systemic iron, hepatic iron reserve, 
erythropoietic activities, hypoxia, inflammation and 
infection. The regulation of hepcidin expression is a 
complex process that requires coordination among 
several proteins. Hepcidin dysregulation contributes 
to developing many diseases such as the anemia of 
chronic disease, iron-refractory iron deficiency 
anemia, cancer, hereditary hemochromatosis, and 
ineffective erythropoiesis such as β-thalassemia. 
Iron regulation by hepcidin is clinically important in 
anemia due to iron overload that occurs in β-
thalassemia2.  
Hereditary hemocromatosis is an iron overload 
disorder that causes damage to several organs and 
is often due to HFE disfunction5.  The HFE plays its 
most prominent role in the regulation of cell iron 
absorption that is accomplished by binding to TFRC 
(Transferrin Receptor). When cell has adequate 
amounts of iron, it competitively binds to TFR and 
prevents iron absorption via endocytosis6. To date, 
many polymorphisms of the HFE have been 
identified out of which H63D and C282Y have been 
reported to be comparatively more frequent7. H63D 
polymorphism entails replacement of aspartic acid 
63 by histidine due to nonsynonymous substitution 
of cytosine with guanine at nucleotide 187 of the 
HFE gene8. Results indicate that the presence of 
H63D causes increase in serum ferritin, compared 
to the wild type. β-Thalassemia is generally 
characterized by potential development of iron 
overload and exacerbated with coinheritance of 
H63D polymorphism9.  
Because c.-582 A>G and p.H63D polymorphisms are 
two of the most common polymorphisms in 
hepcidin and HFE genes, Our aim is to investigate 
the association between the presence of these 
polymorphisms and blood ferritin level in high 
altitude  and low pressure region in Iran.  
 
MATERIALS AND METHODS  
   This cross-sectional study was conducted on 91 
patients referring to the Thalassemia Wards of 
Hajar Hospital in Shahrekord and Shohada hospital 
in Lordegan in 2015. First, the protocol of the study 
was approved by the Ethics Committee of the 
Shahrekord University of Medical Sciences 
(approval code no: 92-7-19). Sample size was 
determined approximately 91 by the formula 
below: 
n = z2p(1-p) / dz 
where z=1.96, p=0.35, and d=0.1. The inclusion 
criteria were history of at least 10 transfusions and 
having taken chelator for at least three months, and 
the exclusion criteria was lack of volunteering to 
participate in the study. The patients were ensured 
that their information would be kept private. The 
patients also provided informed consent for taking 
their blood samples before sample collection and as 
the blood samples were being taken, the patients 
filled out checklists of individual characteristics 
includinggender, age, place of residence, and 
medical history.  
None of the patients had symptoms of active 
hepatic disease and recent or current infection or 
inflammatory disease that may affect the 
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expression of hepcidin and the level of ferritin. The 
patients' information such as the type of chelator 
therapy and the results of MRI T2* assessments 
were obtained from their medical files. Ejection 
fraction (EF) was measured using standard CMR 
sequence and Quantification of iron deposition 
were categorized based on Table 119. The blood 
samples were sent to the Shahrekord Central 
Laboratory to conduct serological examinations and 
measure blood ferritin levels by enzyme-linked 
radioimmunoassay method (Monobind Kit, USA).  
 
Table 1. Quantification of iron deposition in cardiac muscles and lever19  
Myocardial T2*(ms) Myocardial loading 
>20 Normal 
14-20 Mild 
10-14 Moderate 
<10 Severe 
Hepatic T2*(ms) Hepatic loading 
>6.3 Normal 
6.3-2.8 Mild 
1.4-2.7 Moderate 
 
Preparation of genomic templates and PCR 
amplification 
The genomic DNA of the peripheral blood samples 
was extracted by phenol-chloroform extraction 
method10. DNA precipitation was done by using 
pure ethanol and salt at   -20°C. DNA was dissolved 
in 100 μL of TE buffer (Tris-Hcl10 mM, EDTA 1 mM) 
and the final solution was stored at -20°C till later 
use. The total volume of PCR solution was 50 μL. 
Table 2 shows the primers that were designed by 
Primer3 software for PCR amplifications using a 
gradient Gene Atlas G02 gradient thermal cycler 
(ASTEC, Fukuoka, Japan). PCR cycle to amplify a 179 
bp fragment containing c.-582A>G polymorphism of 
hepcidin consisted of one  cycle at 95°C for 10 min 
(initial denaturation), 35 cycles of 95°C for 20 s, 
60°C for 20 s, 72°C for 20 s, and a final cycle of 
extension at 72°C for 5 min.  
PCR cycle to amplify 208 bp amplicon containing 
HFE H36D was similar to that of hepcidin project 
except that the annealing temperature which was 
at 58°C for 20s.  
 
RFLP analysis and sequencing of DNA fragments 
To conduct enzymatic digestion of the PCR product 
with restriction enzyme, 1 µL of the appropriate 
enzymes (Fermentas, New England Biolab) and 2 µL 
of the buffer(1x) according the manufacturer’s 
instruction were added to 10µL of the sample DNA 
and then distilled water was added to the resulting 
solution to a final volume of 20µL. The vial 
containing the solution for enzymatic digestion 
alongside the enzymes was left under temperatures 
specified for each enzyme (Table 2). The enzyme 
Bstu1 was used to determine Hepcidin 
polymorphism. The enzyme Bcl1 was used to 
determine HFE polymorphism.  Then, the products 
of enzymatic digestion were examined by 
electrophoresis using acrylamide gel 8%. 
Fermentase DNA ladder (#SM 0321 bp Gene Ruler 
TM 50) were used to quantitatively analyze target 
DNA. The shifted bands were sequenced by 
Pishgam Co. (Iran) for final confirmation.  
 
Table 2. Primers and enzymes used in PCR-RFLP 
Incubation 
Temperature 
Enzyme Primer pairs Amplicon size Region Gene 
60 ̊C BstuI F: GTGCTGGGCCATATTACTGCT 
R: CACGTGCATAGGTTCTGGCA 
179bp Promoter Hepcidin 
 
50 ̊C 
 
BclI 
 
 
  F: ACATGGTTAAGGCCTGTTGC 
  R: GCCACATCTGGCTTGAAATT 
 
208bp 
 
Exon 2 
 
HFE 
 
Table3. Association between blood ferritin level and genotypes according to t-test 
P- Value Mean level of ferritin Genotype   
0.818 1891±167 AA  
H63D Polymorphism 
 
1975±334 AG  
0.55 
 
1980±186 AA  
C.-582A>G Polymorphism 
 
1760±249 AG  
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Statistical analysis 
Data analysis was conducted by t-test, chi-square 
test, Fisher's exact test, and Pearson correlation 
coefficient in the SPSS version 19. P< 0.05 was 
considered significance level.  
 
RESULTS 
     In this study, 42% of the participants were 
female. The mean age of the participants was 
19±7.5 years and the mean weight was 42±13.6 kg. 
RFLP analysis was performed for all patients 
(Figures 1 and 2). Also, sequencing were confirmed 
the polymorphisms (Figure 3).  Homozygosity for 
both polymorphisms (GG) was very rare.  The types, 
frequency and percentages of used chelator and the 
genotypes are shown in Table 4.  
 
 
 
Figure 1: Detection of the Hepcidin c-582 A>G polymorphism by PCR-
RFLP with Hepcidin promoter primers and digested with restriction 
enzyme Bstu1. Lane M: DNA marker (100bp). Lane uncut: PCR product 
without digestion. Lane A/A: homozygote for wild type allele that 
doesn’t be digested (179 bp). Lane G/G: homozygote for c-582A>G 
variant showing digested bands (102bp and 77bp). Lane A/G: 
heterozygotes for c-582A>G showing normal undigested band (179bp) 
as well as the digested c-582A>G variant (102 pb and 77bp). 
 
Figure 2: PCR-RFLP by H63D primers and Bcl1 as restriction enzyme. 
Lane M: DNA marker (50 bp). Lanes 4, 5, 7: homozygote for wild allele 
cut in to a 141bp and 67 bp fragment (not visible on gel). Lanes 4,5 and 
7: heterozygotes for H63D variant showing normal digested bands (141 
and 67bp) as well as the undigested amplified fragment (208 bp). 
 
 
Figure 3: Sequencing result of a patient with c-582A>G polymorphism in 
promoter of HAMP gene in the position of 1490. Arrow shows the 
position of the polymorphism. 
 
Table 4. The frequency of chelators and genotypes of patients 
 Frequency Percentage 
 
 
 
Chelators 
Desferal 59 %64.3 
Deferiprone 9 %10.7 
Deferasirox 1 %1.2 
Desferal and 
Deferiprone 
18 %1.9 
Desferal and 
Deferasirox 
2 %2.4 
Deferiprone 
and 
Deferasirox 
2 %2.4 
 
C.-582 A>G 
polymorphism 
AA 65 %71.4 
AG 25 %27.4 
GG 1 %1.4 
H63D 
polymorphism 
AA 71 %78 
AG 20 %22 
Both 
polymorphisms 
AG + AG 5 %5.49 
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DISCUSSION 
Mean cardiac MRI (milisecond) was higher in 
patients with AA polymorphism than in those with 
AG polymorphism in the HAMP gene, representing 
decreased precipitation of cardiac iron in the AA 
polymorphism. In contrast, mean liver MRI (ms) was 
lower in patients with AA polymorphism than in 
those with AG polymorphism representing 
increased liver iron concentration in the AA 
polymorphism. Therefore, changes in the heart and 
liver were different. Heart MRI was normal in over 
half of the patients while liver MRI was normal only 
in 1/3 of them. Chi-square test indicated that there 
was no significant association between 
polymorphism and heart MRI (P=0.56). In patients 
with AG polymorphism, qualitative heart MRI was 
normal in 66% of them, mild to moderate in 34%, 
and severe in 0%. According to Spearman 
correlation coefficients, there was an inverse, 
significant correlation between blood ferritin level 
and quantitative heart and liver MRI (r=-0.34, 
p=0.035 and r=-0.001, p=0.609, respectively).  
In this study, we did not observe any significant 
association between blood ferritin level and the c.-
582 A>G polymorphism in the patients that 
regularly consumed chelator, but a difference in 
blood ferritin level between the two genotypes was 
noted (Table 3). This indicates that the 
polymorphism may be effective on the function of 
the HAMP promoter, which can be overwhelmed by 
regular consumption of chelators (environmental 
effect on the gene). However, this difference in 
ferritin level can be due to difference in the 
function of hepcidin protein, which was not 
investigated in the current study, and also the effect 
of other factors on increase in iron overload. A 
study on HAMP function in healthy people 
suggested that due to the key role of hepcidin in 
iron metabolism, different incidence of the hepcidin 
gene caused phenotypic differences among the 
patients. Consistent with our study, a study showed 
that no difference was observed in the ferritin level, 
iron, and transferrin levels in c.-582A > G. However, 
this difference can be attributed to the 
polymorphism role in the gene expression level, 
leading to different gene expression levels 11.  
Environmental conditions can also affect the 
hepcidin gene expression, including the type of 
nutrition and place of residence. For example, the 
people living in the highlands have lower hepcidin 
level compared to those living in the regions of 
lower altitiudes due to hypoxic conditions18. 
Andreani et al.12 reported that the c.-582A>G 
polymorphism caused an increase in ferritin, which 
is inconsistent with our study. To explain this 
inconsistency, we can argue that our participants 
used iron chelators more regularly because the 
mean ferritin level in patients in the study of 
Andreani et al.12 was significantly higher than that in 
our participants. Besides that, given the lack of a 
significant association between the type of chelator 
and ferritin level, the type of chelator cannot be 
considered a confounding factor for ferritin level. 
Another explanation can be related to oxygen 
pressure in the studied region that can affect 
hepcidin gene expression in our participants 
because of the high altitude of Chaharmahal va 
Bakhtiari province.  
Regarding H36D polymorphism, the results of 
Andreani et al.12 are consistent with our study 
because they also observed no significant difference 
in ferritin level between the two groups12. 
Heterozygosity can cause incomplete gene 
permeability13. In our study, people with hepcidin 
gene genotype AA had lower levels of ferritin level 
and higher iron precipitation in the liver. Hepcidin 
gene AG polymorphism in the current study was 
found to cause an increase the iron precipitation in 
the heart and a decrease in the iron precipitation in 
the liver, but the difference was not statistically 
significant. This evidence indicates that study of 
ferritin level alone cannot show the involvement of 
certain organs such as heart and liver.  
In our study, mean ferritin level was 2344±401 mg 
in the splenectomized people that is markedly 
different compared to 1803±143 mg in people 
without splenectomy; however, the difference was 
not statistically significant. In addition, 
endocrinopathies were associated with 
splenectomy, which is possibly due to higher levels 
of ferritin in the splenectomized patients. The 
findings of the  present study imply that the 
presence of G nucleotide substitution in the 
patients leads to increased ferritin level as the 
marker of iron overload probably due to change in 
the transcriptional box in the HAMP promoter that 
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causes change in gene translation factors. Our study 
also showed that the blood ferritin levels were not 
different in patients with β-thalassemia major with 
and without the polymorphisms, which is in 
agreement with the studies of Garewal et al., 
L´opez-Escribano et al., and Mellouli et al.14-16.  
A study to investigate the effects of HFE genotypes 
on iron markers in β-thalassemic carriers indicated 
that β-thalassemia was generally characterized by 
potential development of iron overload and tended 
to exacerbate with coinheritance of H36D 
polymorphism even in the heterozygous cases17. 
This inconsistency in our findings and that study can 
be due to the difference in environmental factors or 
genetic factors that lead to incomplete permeability 
of H63D genotype. Because the sample size of our 
study was small, studies with larger sample size 
should be conducted to further elucidate the role of 
these polymorphisms in iron accumulation in the 
heart.   
 
CONCLUSION 
   Blood ferritin levels were not different in patients 
with β-thalassemia major with and without the 
H63D and c.-582 A>G polymorphisms. However, 
study of these polymorphisms and their association 
with other factors, including environmental factor, 
can help explain increased blood ferritin level in 
patients with β-thalassemia major. 
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